Full Press Release Details
NLS Pharmaceutics Announces an R&D Update
Webcast to Review the Company's Growing Portfolio of Pre-clinical Compounds
Z rich, Switzerland,
January 12, 2023 - NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage
biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central
nervous system disorders, today announced plans to showcase its global strategic R&D progress and platform, as well as its product
candidate and pipeline goals for 2023, with a focus on rare and complex CNS disorders with unmet medical needs. NLS will webcast its upcoming
virtual R&D Day event on the Investors section of the Company's website, www.nlspharma.com, on January 31, 2023, at 10:00 am
Target indication: Idiopathic hypersomnia (IH)
NLS-3 (phacetoperane)
Target: Attention deficit hyperactivity disorder (ADHD)
Target indication: Chronic fatigue syndrome (CFS) associated with
long COVID and cancer patients
NLS-8 (melafenoxate)
Target indication: Amnesia associated with Alzheimer's
Target indication: Kleine-Levin Syndrome
NLS-12 (oxafuramine)
indication: Dementia associated with Lewy Bodies and Parkinson Disease
R&D Day Webcast Information
The Company's R&D Day event will
be held January 31, 2023, at 10:00 am EST and will include a video stream on the Investors section of the Company's website. A replay
will be available on the NLS' website within 48 hours after the event.
About NLS Pharmaceutics
NLS Pharmaceutics Ltd.
(Nasdaq: NLSP) is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally
recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous
system, or CNS, disorders, who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced
management team with a track record of developing and commercializing product candidates. For more information, please visit www.nlspharma.com.
Safe Harbor Statement
This press release contains
expressed or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, NLS is using forward-looking statements
when it discusses the potential benefits to be derived from its product candidates, the inidications that its product candidates may address
and the potential for non-dilutive revenue. These forward-looking statements and their implications are based on the current expectations
of the management of NLS only and are subject to a number of factors and uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially
from those described in the forward-looking statements: changes in technology and market requirements; NLS may encounter delays or obstacles
in launching and/or successfully completing its clinical trials; NLS' products may not be approved by regulatory agencies, NLS' technology
may not be validated as it progresses further and its methods may not be accepted by the scientific community; NLS may be unable to retain
or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop
with NLS' process; NLS' products may wind up being more expensive than it anticipates; results in the laboratory may not translate to
equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials;
NLS' patents may not be sufficient; NLS' products may harm recipients; changes in legislation may adversely impact NLS; inability to timely
develop and introduce new technologies, products and applications; and loss of market share and pressure on pricing resulting from competition,
which could cause the actual results or performance of NLS to differ materially from those contemplated in such forward-looking statements.
Except as otherwise required by law, NLS undertakes no obligation to publicly release any revisions to these forward-looking statements
to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information
about the risks and uncertainties affecting NLS is contained under the heading "Risk Factors" in NLS' annual report on Form
20-F for the year ended December 31, 2021 filed with the Securities and Exchange Commission (SEC), which is available on the SEC's website,
www.sec.gov, and in subsequent filings made by NLS with the SEC.
For additional information:
Marianne Lambertson (investors & media)
NLS Pharmaceutics Ltd.